A dynamic 3‐factor survival model for acute myeloid leukemia that accounts for response to induction chemotherapy

The current study was approached with the assumption that response to induction chemotherapy, in acute myeloid leukemia (AML), overshadows pre‐treatment risk variables in predicting survival and therefore be used as an anchor for a simplified risk model. We considered 759 intensively‐treated patient...

Full description

Saved in:
Bibliographic Details
Published in:American journal of hematology 2022-09, Vol.97 (9), p.1127-1134
Main Authors: Tefferi, Ayalew, Gangat, Naseema, Al‐Kali, Aref, Alkhateeb, Hassan, Shah, Mithun, Patnaik, Mrinal S., Elliott, Michelle A., Hogan, William J., Litzow, Mark R., Hook, Christopher C., Mangaonkar, Abhishek, Viswanatha, David, Chen, Dong, Pardanani, Animesh, Ketterling, Rhett P., DiNardo, Courtney D., Kadia, Tapan M., Ravandi, Farhad, Sasaki, Koji, Begna, Kebede H.
Format: Article
Language:English
Subjects:
Abnormal Karyotype
Acute myeloid leukemia
Chemotherapy
Cytogenetics
fms-Like Tyrosine Kinase 3 - genetics
Hematology
Hematopoietic Stem Cell Transplantation - methods
Hematopoietic stem cells
Humans
Induction Chemotherapy
Karyotypes
Leukemia
Leukemia, Myeloid, Acute - drug therapy
Leukemia, Myeloid, Acute - genetics
Middle Aged
Mutation
Patients
Prognosis
Remission
Remission Induction
Retrospective Studies
Risk factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The current study was approached with the assumption that response to induction chemotherapy, in acute myeloid leukemia (AML), overshadows pre‐treatment risk variables in predicting survival and therefore be used as an anchor for a simplified risk model. We considered 759 intensively‐treated patients with AML, not promyelocytic: median age 60 years; primary 66%, secondary 25%, and therapy‐related 9%; European LeukemiaNet cytogenetic risk category favorable 8%, intermediate 61%, and adverse 31%. Complete remission with (CR) or without (CRi) count recovery was achieved in 608 (80%) patients. After a median follow‐up of 22 months, 503 deaths, 272 relapses, and 257 allogeneic hematopoietic stem cell transplants (AHSCTs) were recorded. Multivariable analysis identified failure to achieve CR/CRi (HR 3.8, 95% CI 3.1–4.8), adverse karyotype (2.2, 1.8–2.8), and age >55 years (2.1, 1.6–2.7) as main risk factors for survival. HR‐weighted scoring resulted in four‐tiered risk stratification: low (0 points; N = 183), intermediate‐1 (1 point; N = 331), intermediate‐2 (2 points; N = 117), and high (≥3 points; N = 128), with respective median survival (5‐year rate) not reached (68%), 34 (37%), 13 (20%), and 5 (5%) months (p 
ISSN:0361-8609
1096-8652
DOI:10.1002/ajh.26630